基于UPLC/LTQ-Orbitrap-MS的消风宣窍汤对变应性鼻炎小鼠尿液代谢组学研究

姜茗宸; 汪受传; 单进军; 谢彤; 陶嘉磊; 汪小蓉

基于UPLC/LTQ-Orbitrap-MS的消风宣窍汤对变应性鼻炎小鼠尿液代谢组学研究

江苏省儿童呼吸疾病中医药重点实验室，南京中医药大学中医儿科学研究所，江苏南京 210023

计量
- 文章访问数: 1080
- HTML全文浏览量: 22
- PDF下载量: 997
- 被引次数: 0
出版历程
- 刊出日期: 2017-11-10

Urine Metabonomic Study on Xiaofeng Xuanqiao Decoction in Treatment of Anaphylactic Rhinitis Based on UPLC/LTQ-Orbitrap-MS

摘要

摘要: 目的分析变应性鼻炎（Allergic rhinitis，AR）模型小鼠尿液内源性代谢物的变化，观察消风宣窍汤对AR异常代谢物的调节作用，从代谢组学的角度探究消风宣窍汤作用机制。方法将60只BALB/c小鼠随机分为对照组、模型组、孟鲁司特组和消风宣窍汤组，以卵蛋白腹腔注射进行致敏，局部鼻黏膜激发的方法建立BALB/c小鼠AR模型，孟鲁司特组和消风宣窍汤组分别给予孟鲁司特钠片和消风宣窍汤，每天2次，连续7d，各组分别于给药最后1天采集尿液样本。采用基于UPLC/LTQ-Orbitrap-MS的代谢组学技术研究各组代谢物的变化，分析药物的干预机制。结果 AR引起小鼠体内酸类、胺类等多种代谢物紊乱。消风宣窍汤主要调控了其中14种异常代谢物的水平，对AR小鼠的干预效果良好。结论 AR小鼠尿液中多个小分子偏离正常状态，消风宣窍汤主要通过对非对称性二甲基精氨酸（ADMA）、N-甲基烟酸、S-腺苷甲硫氨酸(SAMe)、吲哚-2-羧酸(I2CA)、6-氨基己酸(EACA)、咪唑乙酸、1-甲基-4-吡啶-5-羧酰胺(M4PY)的上调和1-甲基组胺的下调，改善组氨酸代谢和半胱氨酸和蛋氨酸代谢以达到治疗效果。
- 消风宣窍汤 /
- UPLC/LTQ-Orbitrap-MS /
- 代谢组学 /
- 变应性鼻炎 /
- 生物标记物
Abstract: OBJECTIVE To observe the regulation of Xiaofeng Xuanqiao Decoction(XFTQ) on abnormal metabolites by analyzing the changes of endogenous metabolites in urine of anaphylactic rhinitis(AR) mice， and to explore the mechanism of Xiaofeng Xuanqiao Decoction on treating AR from the perspective of metabonomics. METHODS 60 BALB/c mice were divided into normal group， model group， montelukas group and XFTQ group. Intraperitoneal injection of OVA and local nasal mucosa stimulation was used to establish AR model. Montelukast group and XFTQ group were given montelukast sodium tablets and Xiaofeng Xuanqiao decoction， respectively， for 7d. Urine samples were collected from each group on the last day of administration. UPLC/LTQ-Orbitrap-MS was applied to analyze the metabolic profile changes of each group and the intervention mechanism of drugs. RESULTS AR disordered the metabolism of acid， amine and others in mice. Xiaofeng Decoction mainly regulated the levels of 14 kinds of abnormal metabolites， and it showed good intervention effect on AR mice. CONCLUSION Small molecule metabolites in AR mice are deviated from the normal group. Xiaofeng Xuanqiao Decoction improves the histidine metabolism and cysteine and methionine metabolism to achieve therapeutic effect， mainly through the up-regulation of asymmetric dimethyl-arginine（ADMA）， N-methylnicotinic acid， S-adenosyl-L-methionine(SAMe)， indole-2-carboxylic acid(I2CA)， 6-aminocaproic acid(EACA)， imidazole-4-acetic acid，1-methyl-4-pyridone-5-carboxamide(M4PY)， and the down-regulation of 1-methylhistamine.
- Xiaofeng Xuanqiao Decoction /
- UPLC/LTQ-Orbitrap-MS /
- metabonomics /
- rheumatoid arthritis /
- biomakers

HTML全文

参考文献(38)

[1]	BLAISS MS. Pediatric allergic rhinitis: physical and mental complications[J]. Allergy Asthma Proc，2008，29(1):1-6.
[2]	张罗，周兵，韩德民，等.变应性鼻炎研究进展(二):药物治疗[J].耳鼻咽喉头颈外科.2003，10(6):368-374.
[3]	ZHANG L， ZHOU B， HAN DM，et al. Research progress of allergic rhinitis(2): drug therapy[J].Chin Arch Otolaryngol Head Neck Surg，2003，10(6):368-374.
[4]	李萌.汪受传教授从伏风论治小儿鼻鼽经验总结及机理研究[D].南京：南京中医药大学，2014.
[5]	LI M. Professor WANG Shou-chuan's Experience and Mechanism Research in Treating Pediatric Bi Qiu From Latent Wind[D].Nanjing: Nanjing University of Chinese Medicine，2014.
[6]	陶嘉磊，汪受传，姜茗宸，等.消风宣窍汤对小鼠变应性鼻炎模型效应机制研究[J].南京中医药大学学报，2017，33(2):213-215.
[7]	TAO JL，WANG SC，JIANG MC，et al.Acting mechanism of Xiaofeng Xuanqiao Decection for on mice model of allergic rhinitis[J].J Nanjing Univ Tradit Chin Med，2017，33(2):213-215.
[8]	LI P，CUI Y，SONG G，et al. Phenotypic characteristics of nasal mast cells in a mouse model of allergic rhinitis[J].ORL， 2014， 76(6):303-313.
[9]	贾伟.医学代谢组学[M].上海:上海科学技术出版社，2011：1-2.
[10]	JIA W. Medical Metabonomics[M].Shanghai: Shanghai scientific and technical publishers，2011：1-2.
[11]	陆艳，周学平，谢彤.类风湿关节炎的代谢组学研究进展[J].中华中医药杂志.2015，30(10):3585-3588.
[12]	LU Y，ZHOU XP，XIE T.Progress on metabonomics research of rheumatiod arthritis[J].China J Tradit Chin Med Pharm，2015，30(10):3585-3588.
[13]	KERR J.Identification of urocanic acid in the urine in status asthmaticus[J].Lancet，1963，2(7310):709-710.
[14]	WENZEL SE， FOWLER AA， SCHWARTZ LB. Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma[J]. Am Rev Respir Dis，1988，137(5):1002-1008.
[15]	BROWN MJ，IND PW，CAUSON R，et al. A novel double-isotope technique for the enzymatic assay of plasma histamine: application to estimation of mast cell activation assessed by antigen challenge in asthmatics[J].J Allergy Clin Immunol，1982，69(1):20-24.
[16]	SNOWDEN S，DAHLEN SE，WHEELOCK CE. Application of metabolomics approaches to the study of respiratory diseases[J]. Bioanalysis，2012，4(18):2265-2290.
[17]	王向东，韩德民，周兵，等. 上下呼吸道炎症反应相关性研究[J].中华耳鼻咽喉头颈外科杂志， 2003， 38(4):247-250.
[18]	WANG XD， HAN DD，ZHOU B，et al.A study of the link between upper and lower respiratory inflammation[J].Chin J Otorhinolaryngol Head Neck Surg，2003，38(4)，247-250.
[19]	范春涛，鹿道温，王欣，等.变应性鼻炎和哮喘的相关性分析[J].中国耳鼻咽喉头颈外科，2006，13(2):103-105.
[20]	FAN CT，LU DW，WANG X，et al.Study of the relationship between allergic rhinitis and asthma[J]. Chin Arch Otolaryngol Head Neck Surg，2006，13(2):103-105.
[21]	SZAFARZ M，LOMNICKA M，STERNAK M，et al. Simultaneous determination of nicotinic acid and its four metabolites in rat plasma using high performance liquid chromatography with tandem mass spectrometric detection (LC/MS/MS)[J].J Chromatogr B Analyt Technol Biomed Life Sci， 2010，878(11/12)， 895-902.
[22]	GEBICKI J，SYSA-JEDRZEJOWSKA A，ADAMUS J，et al. 1-Methylnicotinamide: a potent anti-inflammatory agent of vitamin origin[J].Pol J Pharmacol，2003，55(1)，109-112.
[23]	ZHAO XJ，HAO F，HUANG C，Et al.Systems responses of rats to mequindox revealed by metabolic and transcriptomic profiling[J].J Proteome Res，2012，11(9):4712-4721.
[24]	TESTA B，MESOLELLA M，TESTA D，et al.Glut athione in the upper respiratory tract[J].Ann Otol Rhinol Laryngol，1995，104(2):117-119.
[25]	WATSON WH，ZHAO YM， CHAWLA RA.Sadenosylmethionine attenuates the lipopoysaccharideinduced expression of the gene for tumour necrosis factor α[J]. Biochem，1999，34(2):21-29.
[26]	陈明亮，易龙，金鑫，等. 白藜芦醇对TNF-α诱导的血管内皮细胞炎性反应的影响[J]. 第三军医大学学报， 2012， 34(13):1255-1258.
[27]	CHEN ML，YI L，JIN????????????????戠牯? resveratrol on TNF-α-induced vascular endothelial inflammation in vitro[J]. J Third Mil Med Univ， 2012， 34(13):1255-1258.
[28]	YILDIRIM AO，BULAU P，ZAKRZEWICZ D，et al.Increased protein arginine methylation in chronic hypoxia-role of protein arginine methyltransferases[J].Am J Respir Cell Mol Biol，2006，35(4):436-443.
[29]	MAARSINGH H，PERA T，MEURS H. Arginase and pulmonary diseases[J].Naunyn Schmiedebergs Arch Pharmacol，2008，378(2):171-184.
[30]	余洪猛，刘颖，郑春泉，等.白细胞介素-4及干扰素-γ在实验性变应性鼻炎动物血清中的表达[J].临床耳鼻咽喉科杂志，2003，17(5):299.
[31]	YU HM，LIU Y，ZHENG CQ，et al.Expression of interleukin - 4 and interferon - γ in serum of experimental allergic rhinitis[J].J Clin Otorhinolaryngol Head Neck Surg，2003，17(5):299.
[32]	叶建明，周建军，管建丽.变应性鼻炎患者脱敏治疗前后IL-8、IL-10含量的变化[J].放射免疫学杂志，2010，23(1):97-98.
[33]	YE JM， ZHOU JJ， GUAN JL. Changes of IL - 8 and IL - 10 contents in patients with allergic rhinitis before and after desensitization[J].J Radioimmunol，2010，23(1):97-98.
[34]	SUN KH，YU CL，TANG SJ，et al. Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta， IL-6， IL-8， IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis[J].Immunology，2000，99:352-360.
[35]	GREILICH PE，BROUSE CF，WHITTEN CW，et al.Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels:a randomized， double-blind，placebo-controlled study of epsilon-aminocaproic acid and aprotinin[J].Thorac Cardiovasc Surg，2003，126(5): 1498-1503.
[36]	TIWARI RK，SINGH D，SINGH J，et al. Synthesis and antibacterial activity of substituted 1，2，3，4-tetrahydropyrazino [1，2-a] indoles[J]. Bioorg Med Chem Lett， 2006，16(2):413-416.
[37]	BOGER DL， FINK BE， HEDRICK MP. A new class of highly cytotoxic diketopiperazines[J]. Bioorg Med Chem Lett， 2000，10(10):1019-1020.
[38]	LEHR M. 3-(Octadecanoylaminomethyl)indole-2-carboxylic acid derivatives and 1-methyl-3-octadecanoylindole-2-carboxylic acid as inhibitors of cytosolic phospholipase A2[J]. Arch Pharm (Weinheim)，1996，32???????????????????